Transplantation of CD95 ligand-expressing grafts: Influence of transplantation site and difficulty in protecting allo- and xenografts

Transplantation

Volumn 64, Issue 7, 1997, Pages 1050-1054

  Seino, Ken Ichiro ^a,b   Kayagaki, Nobuhiko ^a   Tsukada, Nobuyuki ^a   Fukao, Katashi ^c   Yagita, Hideo ^a   Okumura, Ko ^a  

^a JUNTENDO UNIVERSITY   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; FAS ANTIGEN; LIGAND;

ANIMAL CELL; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNE DEFICIENCY; KIDNEY TRANSPLANTATION; NONHUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; T LYMPHOCYTE;

ANIMALS; ANTIGENS, CD95; CELL LINE; CRICETINAE; FAS LIGAND PROTEIN; FEMALE; GRAFT SURVIVAL; KIDNEY TRANSPLANTATION; LEUKEMIA L5178; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, INBRED DBA; MICE, NUDE; NEOPLASM TRANSPLANTATION; RECOMBINANT PROTEINS; TRANSFECTION; TRANSPLANTATION, ISOGENEIC;

EID: 0030864939     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199710150-00018     Document Type: Article

References (17)

1. Nagata S, Golstein P. The CD95 death factor. Science 1995; 267: 1449.
2. + T cells. Immunol Rev 1995; 146: 223.
3. Suda T, Takahashi T, Golstein P, et al. Molecular cloning and expression of the CD95 ligand, a novel member of the tumor necrosis factor family. Cell 1993; 75: 1169.
4. Bellgrau D, Gold D, Selawry H, et al. A role for CD95 ligand in preventing graft rejection. Nature 1995; 377: 630.
5. Griffith TS, Brunner T, Fletcher SM, et al. CD95 ligand-induced apoptosis as a mechanism of immune privilege. Science 1995; 270: 1189.
6. Lau HT, Yu M, Fontana A, et al. Prevention of islet allograft rejection with engineered myoblasts expressing CD95L in mice. Science 1996; 273: 109.
7. Yagita H, Seino K, Kayagaki N, et al. CD95 ligand in graft rejection. Nature 1996; 379: 682.
8. Seino K, Kayagaki N, Okumura K, et al. Antitumor effect of locally produced CD95 ligand. Nature Med 1997; 3: 165.
9. Kayagaki N, Kawasaki A, Ebata T, et al. Metalloproteinase-mediated release of human CD95 ligand. J Exp Med 1995; 182: 1777.
10. Kayagaki N, Yamaguchi N, Nagao F, et al. Polymorphism of murine CD95 ligand that affects the biological activity. Proc Natl Acad Sci USA 1997; 94: 3914.
11. Gotoh M, Maki T, Kiyoizumi T, et al. An improved method for isolation of mouse pancreatic islets. Transplantation 1985; 40: 437.
12. Allison J, Georgiou HM, Strasser A, et al. Transgenic expression of CD95 ligand on islet β cells induces a granulocytic infiltration, but does not confer immune privilege upon islet allografts. Proc Natl Acad Sci USA 1997; 94: 3943.
13. Yamada K, Takane-Gyotoku N, Yuan X, et al. Mouse islet cell lysis mediated by interleukin-1-induced Fas. Diabetologia 1996; 39: 1306.
14. Allison J, Malcolm L, Culvenor J, et al. Overexpression of β2-microglobulin in transgenic mouse islet β cells results in defective insulin secretion. Proc Natl Acad Sci USA 1991; 88: 2070.
15. Kemp CB, Knight MJ, Scharp DW, et al. Effect of transplantation site on the results of pancreatic islet isografts in diabetic rats. Diabetologia 1973; 9: 486.
16. Wilbanks GA, Mammolenti M, Streilein JW. Studies on the induction of anterior chamber-associated immune deviation (ACAID): III. Induction of ACAID depends upon intraocular transforming growth factor-β. Eur J Immunol 1992; 22: 165.
17. Sharma K, Ziyadeh FN. The transforming growth factor-β system and the kidney. Semin Nephrol 1993; 13: 116.